深圳市亦诺微医药科技有限公司 Immvira Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment 2024-03-15 13:56
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results 2023-11-10 08:00
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor 2023-08-23 10:51
ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023 2023-06-07 08:00
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer 2023-04-21 09:06
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting 2023-04-19 08:29
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China 2023-03-30 08:00
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma 2023-02-09 08:00
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round 2022-10-26 14:26
ImmVira announced to launch the construction of Global R&D and Commercialization Base 2022-10-18 16:22
ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation 2022-08-08 08:30
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities 2022-07-21 08:00
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S. 2022-04-20 08:00
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China 2022-03-02 09:07
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors 2022-01-25 08:30
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data 2022-01-19 08:30
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial 2021-08-11 10:45
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial 2021-08-06 19:50
ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials 2021-07-19 08:30
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China 2021-06-12 11:16
1 2